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La Terapéutica es la rama de las ciencias de la salud, que se ocupa de los medios empleados y su forma 
de aplicarlos en el tratamiento de las enfermedades con el fin de aliviar los síntomas o de producir 
la curación. Hoy en día existen al alcance multitud de herramientas terapéuticas para combatir los 
diversos problemas de salud a los que se hace frente día a día. Con esta evolución de la Medicina, 
es inevitable que vayan surgiendo cada vez más y mejores estrategias que conducen a un espectro 
terapéutico más innovador. Dentro de las nuevas estrategias, nos encontramos con la Terapia Génica 
que es una de las que más potencial tiene actualmente. Este tipo de terapia se basa en utilizar material 
genético como sustancia activa frente a diversas patologías y es aquí donde se encuentra el centro de 
atención de la presente revisión bibliográfica. Con la gran demanda de sistemas que vehiculizan el 
material génico han surgido en la última década, diversas formas de transportar dicho material. Una 
de estas formas consiste en el empleo de vectores no virales. Los cuales no son más que transfectores 
que eluden los problemas inherentes al empleo de estructuras víricas, como son las reacciones 
inmunológicas. La polietilenimina ha emergido como el polímero más prometedor en este ámbito 
por múltiples razones las cuales serán ilustradas en el presente trabajo.
Los objetivos de la presente revisión son otorgar al lector un conocimiento sobre qué es la 
polietilenimina, porqué suscita tanto interés hoy en día en terapia génica, y cuáles son algunas de 
sus aplicaciones, haciendo especial hincapié en el tratamiento del cáncer.
PALABRAS CLAVES:  Cáncer, Polietilenimina, Terapia génica.
ABSTRACT 
Therapy is a branch of health science that deals with the means used and the manner of application 
in the treatment of diseases in order to relieve symptoms or produce a cure. Today there are many 
therapeutic tools available to combat the diverse health problems faced daily.  With this evolution 
of medicine, it is inevitable that more and better strategies emerge leading to a more innovative 
therapeutic spectrum.   Within the new strategies, we find that gene therapy is currently one with 
most potential.   This type of therapy is based on using genetic material as an active substance against 
various pathologies and it is on which this literary review is focused.  With the high demand for 
systems that vehiculize genetic material, diverse forms of carrying said material have emerged in the 
past decade.  One of these forms consists of the use of non-viral vectors. The non-viral vectors act 
as transfectants that evade problems inherent to the use of viral structures such as immunological 
reactions.  Polyethylenimine has emerged as the most promising polymer in this field for many 
reasons which will be illustrated in this paper.  
The objectives of this review are to give the reader an understanding of what Polyethylenimine is, 
why it has produced so much interest today in gene therapy, and what its applications are, with 
special emphasis on cancer treatment.  
KEYWORDS: Cancer, Gene therapy, Polyethylenimine, .
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INTRODUCTION
Therapy advances, reinvents itself and looks for new 
ways to address health problems. Nanotechnology, that 
could dominate as the therapy used to carry out nanoscale 
systems, has lead to significant progress in recent years1. 
In this new therapeutic field multiple systems necessary 
for the application and development of said technologies 
have appeared such as solid lipid particles, polymeric 
nanoparticles or liposomes2. Each one of these presents its 
own specific advantages and disadvantages that allow us 
to chose the most suitable vehiculization for each different 
situation and therapy.  However, the choice does not 
stop there. These different types of systems, in turn, can 
be composed of different materials in order to optimize, 
even more, its use in more specific applications3. The 
materials used are very diverse, such as magnetite4or 
maghemite iron oxides5, and control the location of the 
system thanks to an external magnetic field gradient; fatty 
acids, elements fundamental to the formation of liposomes 
that help the vehiculization of soluble substances or system 
functionalization and, finally, cite the polymers, a large 
group of substances with diverse applications in which we 
find the focus of this paper, Polyethylenimine (PEI).
PEI is an organic polymer that has experienced growing 
interest in recent years in medicine.  This is due to its 
ability to complex DNA and protect itself once inside the 
cell, being the base of the majority of non-viral vectors 
used in transfection.  Research into non-viral vectors is a 
booming field given the promise of gene therapy and the 
problems inherent in using the same viruses as they are, 
among others, immune reactions.  
In this paper, we delve into the literature of the polymer 
thanks to major bibliographic search tools with the intent 
of clarifying what the position of PEI is in the field of new 
therapies, specifically in gene therapy, and how it can be 
used in the treatment of malignancies.
BIBLIOGRAPHIC OVERVIEW
The first literary work that makes reference to PEI, data 
from 1965, analyses its capacity as a protecting agent 
against the flocculation of colloidal suspensions of gold 
particles yielding values much lower than the average 
of other substances used for this purpose6. It wasn’t 
until 1998 when references began to appear in the field 
of nanotechnology and directly in nanomedicina7. From 
that year, references, as well as article citations referring 
to the same, began to increase significantly. In order to 
get an overview of the importance and the state in which 
PEI is found in research, a bibliographic search was done 
between 2000 and 2012 in an important scientific biomedical 
database with four different search criteria: PEI, PEI + 
nanomedicine, magnetofection and PEI + gene delivery. 
Such criteria were considered because they not only allow 
the appreciation of the volume of work on the polymer but 
also illustrated how the works were distributed in its most 
relevant applications; one of them being gene delivery. 
The addition of a criterion such as magnetofection allowed 
us to detect how new terms within gene therapy continue 
appearing for increasingly specific processes that look for 
an improvement in genetic material transportation.  The 
results, classified by year, are shown in figure 1.  
As one can see in the figure, there is no denying the growing 
importance PEI has each passing year in research. It can 
be seen that from the year 2000 PEI has been used in gene 
delivery and the involvement of said polymer has been 
such that it is now the protagonist in more than half of the 
works in this field. Equally, terms like nanomedicine and 
magnetofection have gradually been incorporated into the 
surroundings of PEI. More specifically, nanomedicine has 
also become a field with multiple literary works relating 
to it. If we carefully analyze the figure, we can see that not 
all the publications on PEI encompass gene delivery and 
nanomedicine; this is because the polymer presents many 
other uses such as the creation of synthetic enzymes or the 
functionalization of other systems.  Likewise, not all the 
publications on gene delivery correspond to the field of 
nanomedicine and magnetofection. This is because gene 
delivery is not a process exclusive to nanomedicine or 
gene therapy but can also be used in transfection processes 
in other fields such as industrial or microbiological.  In 
conclusion, gene delivery is the field where PEI is finding 
more prominence and application in this decade and, as 
one can see, it is still a very current issue that has yet to 
find its limits.  
Figure 1.  Number of publications dealing with PEI as a 
function of time
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Figure 2. Chemical structure of PEI.
TYPES OF POLYETHYLENIMINE
PEI is an organic polymer in which the chain of carbon 
atoms that has a nitrogen heteroatom for every two carbon 
atoms.  The presence of those nitrogen atoms confers a strong 
positive surface charge from which most of its properties and 
uses are derived.  A sample of this surface charge can be 
found in the coating of magnetic cores of magnetite whose 
surface charge, once treated with citric and according to 
results obtained in its own research, generated values 
of -40.1 ±3.7 mV.  After its polymer coating those values 
shifted between 33.7±1 mV and 74.4±4.8 mV depending on 
conditions used to obtain it.  
Before talking about the different properties and how they 
are conditioned by mainly two variables, such as its degree 
of cross-linking and its size, different types of PEI and how 
to obtain it will be exhibited in order to better understand 
the concepts later on.   
There are two distinct types of PEI; lineal PEI (IPEI) and 
cross-linked PEI (bPEI).  Both differ in structure and the 
degree of branching of the chains, IPEI being strictly linear 
and bPEI being cross-linked.  Both structures can be seen 
in figure 2. 
One of the methods of obtaining bPEI consists of the 
controlled polymerization reaction of aziridine or, 
more commonly known, ethyleneimine.  This reaction 
produces PEI with a high degree of branching as the new 
ethyleneimine monomers have a higher probability of 
joining the more substituted nitrogen atom.  
On the other hand, we have the IPEI that can be obtained 
through a reaction of ring-opening polymerization of 
N (2-tetrahydropyranyl) aziridine.  The chemistry of 
the reaction makes the monomers from this opening 
incorporate and form a chain, contrary to the previous 
reaction, and produces long lineal chains of PEI.  
In addition to the degree of branching of the polymer, 
another determining property is the size of the polymer 
itself.  The range of PEIs regarding molecular weight (MW) 
is also very high and can oscillate from 11 KDa to 800 KDa 
describing the PEIs as having low, intermediate or high 
MW8.  
Concluding, we can find six types of PEI: IPEI of high, 
intermediate and low MW and bPEI of high, intermediate 
and low MW.
MAIN CHARACTERISTICS OF PEI
The two main characteristics to consider of PEI are the 
degree of cross-linking and it’s MW, especially if we are 
going to talk about its relation with genetic material and its 
capacity to vehiculize it.  Below, small sections are devoted 
to speak about each one.  
Degree of Branching
How the degree of cross-linking influences the behavior 
or the polymer is a fact that continues rediscovering 
itself.  Currently, it can be said that the higher the degree 
of cross-linking, the higher quantity of tertiary and 
primary amines appears in the chemical structure of the 
polymer, with a consecutive loss of secondary amines, 
reaching the extreme case of comparing IPEI, which only 
contains secondary amines, with bPEI, which contains 
approximately 25% of secondary and tertiary amines and 
50% of primary amines.  These different proportions of 
amines significantly influence several of the properties 
required in evaluating gene therapy such as cell viability, 
the ability and method of complexing DNA, the ability of 
transfection, and nuclear promotion, etc.  Because of this, 
we can have PEIs significantly different from each other 
depending on the degree of cross-linking9.  As it may be 
deemed crucial in the vehiculization of genetic material, 
how the degree of cross-linking influences the ability and 
method of complexing DNA as well as the differences that 
can be found between IPEI and bPEI will be explained.  
bPEI is capable of complexing DNA in small spherical 
vesicles of nanometric sizes and in a wide variety of 
environments.  However, in this environment, IPEI forms 
much larger micrometric complexes and must resort to 
a salt-free medium and elevate the N/P ratio, consisting 
of the ratio of nitrogen atoms belonging to PEI compared 
to those of phosphorous of the genetic material, in order 
to obtain complexes of similar sizes and shapes to those 
obtained with bPEI.  Apart from this, it has been observed 
that the IPEI complexes presented, in general, increased cell 
viability, greater capacity to promote cellular localization 
and, ultimately a greater power of transfection8,10.  Much 
has been discussed about this fact because, in principle, 
one would expect a greater capacity for transfection of bPEI 
due to its greater ease (“proton sponge”) of maintaining 
the pH of the endocytic vesicle environment when the 
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cell attempts to destroy its contents downloading a large 
amount of protons on it to lyse it.  This property of bPEI 
is justified by its wide variety of amines and it is because 
of this fact that it is considered more efficient because it 
protects the genetic material once inside the cell.  Returning 
to transfection efficiency, some authors argue that the 
disparity in the results obtained in the field for IPEI and 
bPEI find their explanation in a fact that may be overlooked, 
such as the cell cycle phase where the cells are transfected. 
Those authors have presented papers as evidence that IPEI 
shows less dependency on the cell cycle than bPEI at the 
time of the transfection of target cells.  This means that 
when testing on cell lines or cultures that exhibited low or 
no growth rate, IPEI will show greater efficiency while if 
testing on cell lines or cultures with higher growth rate, 
bPEIs will be found11.  
Size
The variety of MW of PEI is huge.  The interval of sizes 
oscillates between a few KDa and 800 KDa.  With the 
intention of using the most suitable PEI for each type of 
biomedical use, many authors try to relate the size with 
different behaviors of the polymer and the system to be 
used.  Discussing gene delivery, a pair of well-known 
relationships is the influence of the size of PEI on the in 
vivo toxicity of the system and in the transfection efficiency. 
PEIs with greater MW, for example, 800 KDa, have been 
described as being more toxic than those with a lower MW, 
for example 25 KDa.  However, in contrast, the former are 
much more efficient if we talk in terms of transfection. 
This has been a dilemma since the potential of PEI in gene 
therapy was discovered and research has been done to 
find the most suitable size for gene delivery obtaining, 
in an acceptable range of toxicity, the greatest possible 
transfection efficiency.    This search finally gave the weight 
of 25 KDa, reason for which it is the most used PEI MW in 
gene vehiculization12.
OTHER USES NOT RELATED TO THE TRANSPORT 
OF GENETIC MATERIALS.
Although we will focus primarily on the uses of PEI as a 
gene carrier, one cannot ignore that other significant parts 
of the polymer exists, regarding uses that do not correspond 
to gene therapy.  Some of the most frequent uses of PEI as a 
polymer outside of gene therapy are:
The electric surface properties, markedly positive 1. 
characteristics of PEI, provide it with a unique ability 
to capture different molecules.  This capability is 
used in the industry to create very specific chemical 
sensors in complex chemical environments.  In these 
environments it is more difficult to discriminate 
between the molecule of interest and the rest of the 
molecules and it’s more complicated to obtain a good 
sensor.  The synthesis and use of carbon nanotubes 
functionalized with PEI to be used as a method of 
rapid analysis that detects the degree of rancidity of 
soybean oil could be an example of great interest in 
the food industry13. 
Another application is the creation and study of 2. 
synthetic enzymes.  In them, bPEI is the enzyme body 
on which necessary chemical groups are incorporated 
to provide it with the desired form and reactive 
capacity.  bPEI is used in this field for several reasons: 
its cross-linked structure, its high solubility in water 
and its large number and variety of amino groups ready 
to be functionalized.   A set-up and characterization of 
how bPEI can be used for obtaining various enzymatic 
molecules has been described by Junghun Suh et al. in 
some of their publications14. In them, they studied how 
enzymes with a bPEI base have different behaviors 
versus pH ranges such as the conformational behavior 
or its ability to continue to attract some ligands.       
PEI also can be used as a catalyst for the synthesis of 3. 
star polymers, a special formation consisting of many 
polymer chains that converge at a single point.  This 
paper15 describes a hybrid system with two polymers, 
PEI and poly(ε-caprolactone), where the core from 
which the poly(ε-caprolactone) chains start is formed 
by PEI.  PEI acts not only as an initiator in the synthesis 
of polymerization but also as a part of the star polymer 
allowing the use of both as a nanocarrier that can hold 
and transport lipophilic substances from within thanks 
to the hydrophilic PEI.  
Another possibility within the pharmaceutical field is 4. 
the use of the polymer as part of drug carrier systems. 
The possibilities are numerous and the polymer 
can be part of magnetic nanoparticles16, nanogels17, 
liposomes18, and micelles19 among others.  Regarding 
the latter, to give an example, Li Yan Qui et al. vehiculize 
an active antitumor, such as doxorubicin, in a micellar 
system formed by PEI and poly(ε-caprolactone).
Recently, a new way of applying magnetic cores 5. 
for obtaining magnetic resonance imaging (MRI) of 
tumors in vivo has appeared.  This new technique 
consists of using small molecules known as aptamers 
capable of concentrating specifically on tumor cells of 
the tissue in vivo.  This permits them to act as probes 
that carry magnetic cores required for obtaining 
magnetic resonance imaging (MRI).  However, the 
use of these molecules consisting of small nucleic acid 
sequences, presents certain difficulties.  One of these 
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difficulties is its rapid degradation when circulating 
in the bloodstream.   The use of PEI to protect these 
systems formed by aptamers and magnetic cores has 
demonstrated that it ensures that the vehicle remains 
in the blood longer and the technique can be applied 
to avoid the half-life problems of the aptamers20.
POLYETHYLENIMINE AND GENE THERAPY
DNA complexing process
Before delving into the uses of PEI in gene therapy to 
treat cancerous pathologies, it´s important to know how it 
interacts with genetic material to form nanoparticles (NP) 
that can act as a non-viral vector.  For this, how the N/P 
ratio and the environment where the synthesis of the non-
viral vector is carried out influence the formation thereof 
and how this can influence the efficiency of transfection 
will be briefly commented on.  
N/P ratio
The NP ratio is probably the condition to take into 
most account when forming the non-viral vector.  It is 
fundamental to choose the right proportion of nitrogen 
atoms belonging to PEI compared to the phosphorous 
genetic material because it will determine the overall 
charge of the complex as well as how and with what 
intensity PEI will be joined with the genetic material21.  It is 
necessary to take into consideration that the overall charge 
of the vector should be predominantly positive, since the 
interaction with the cell surface depends on it. However, 
it cannot be excessive because a cationically elevated 
complex is cytotoxic22.  Something else to take into account 
is that the “proton sponge” capacity should not be altered 
by an excess of nitrogens occupied with the phosphates 
of the genetic material.  This would result in an excess of 
amines available for buffering the proton discharge made 
by the cell when the nanoparticle is internalized into it 
causing the consequent destruction of genetic materials. 
Finally, the interaction established between PEI and genetic 
material should not be too strong because it would prevent 
dissociation, and therefore, the release of the genetic 
material of the system after overcoming the intracellular 
obstacles.  There are many researchers who have worked 
on this and it is important to note that, in view of the 
results, a specific N/P ratio exists for each PEI-genetic 
material pair. This makes the parameter an objective that 
should be studied, since it not only determines the viability 
of target cells but also, through the previously described 
mechanisms, determines the transfection efficiency of the 
NP23,24.  
Environment
As for the composition of the medium where the entrapment 
of genetic material by PEI takes place, the reaction conducted 
between them is quite simple.  Normally a saline solution 
of NaCl undergoes mechanical agitation with the genetic 
material, while another solution of PEI is added little by 
little25,26,27.  In this way, PEI fuses together with the genetic 
material, which can be anything from plasmids to small 
sequences of RNAi, forming the NPs.  However, over time, 
there has been an increase in exploring ways of trying to 
control the process by varying the conditions under which 
it is performed.   This is interesting because the way that 
the NP is formed is going to be crucial for the transfection 
process.  Numerous studies exist that demonstrate how the 
use of appropriate conditions can positively influence the 
transfection efficiency, such as the presence of surfactants28 
or the use of glucose in the medium instead of NaCl29.  
Use of PEI in gene therapy
Gene therapy uses two types of vehicles to facilitate 
the delivery of genetic material to the site of action for 
therapeutic purposes. Both types of vectors are classified 
according to their nature as follows:
Viral vehicles: more traditional in gene therapy. Its 1. 
main characteristics are its high power of transfection, 
natural tropism towards specific cell types, intrinsic 
ability to escape the endolysosomes and natural 
mechanisms to direct the genetic material towards the 
core. On the contrary, they are immunogenic capable 
vehicles, which can produce chromosomal insertions 
or activate proto-oncogenes. Additionally, they have 
a limited capacity of genetic material and in turn can 
produce toxic reactions or may be contaminated by 
live viruses30,31.
Non-viral vehicles: arise in response to the growing 2. 
interest in gene therapy and the need to overcome the 
main problems of viral vectors. While they can achieve 
immunogenic vectors, without the risk of insertions 
and with a higher capacity of genetic material, the 
transfection efficiency is significantly lower. Here is 
where PEI ranks as the leading exponent of non-viral 
vectors in gene therapy30,31,32.
Non-viral vectors have a prominent role in numerous 
studies focused on the treatment of multiple types of 
diseases such as cancer33, infections34, circulatory disease35 
and autoimmune or recessive genetic defects like cystic 
fibrosis36. Below, we will describe the main cancer treatment 
strategies based on gene therapy and the decisive role non-
viral vectors formed by PEI play in some of them:
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Immunogenic therapy: this type of therapy aims to 1. 
improve and focus an individual’s immune response 
against malignant cells. The idea of this strategy 
consists in using genes that modify target cells so that 
they acquire the ability to attract and enhance the 
immune response against them. This can be achieved 
either by providing them the ability to synthesize 
chemotactic molecules or allowing them to behave 
as antigen presenting cells30. The IL-2 is a known 
immunogenic response stimulant and its use in the 
treatment of cancer is being researched. However, 
due to problems in its stability in vivo and numerous 
adverse affects, its administration to the patient does 
not constitute a good therapeutic strategy. The use of 
PEI to specifically transfect tumor cells in such a way 
that it overexpresses the molecule allowing a selective 
localization thereof is a promising way to avoid the 
problems mentioned above37.
Suicide gene therapy: in this type of therapy the 2. 
transfection of target cells is produced in a way that they 
acquire the ability to produce a non-native enzyme. 
Previously, a patient was administered a harmless 
substance, or as harmless as possible, that acted as a 
prodrug. This, to reach the transfected cells, will be 
modified by an induced enzyme converting itself into 
an active substance. In this review38, Springer, C. J. et 
al. explain step by step the implementation of suicide 
therapy in cancer treatment, with emphasis on the 
most used non-native enzyme prodrug pairs.  Some of 
these pairs are CB 1945, bacterial nitroreductase and 
6-methoxypurine arabino nucleoside, viral thymidine 
kinase.  In this other article39, Bing Liang et al. use a 
non-viral vector formed by polyethylene glycol, folic 
acid and PEI (PEG-AF-PEI) to induce the production 
of a non-native enzyme and an immunogenic agent. 
These are the 5-fluorocytosine, cytosine deaminase 
(5-FC/CD) and the inducing ligand of TNF-related 
apoptosis, respectively.  Applying the prodrug, in 
this case 5-fluorocytosine, a synergistic relationship 
develops between both types of therapy, suicide gene 
therapy and immunogenic therapy, thereby achieving 
greater tumor efficacy with the combined use of both 
therapies as opposed to the use of just one. 
Antiangiogenic Therapy: Heightened growth and 3. 
metabolic activity are common features of most 
tumors.  In order to carry out these processes, the 
tumor mass requires a large supply of nutrients 
and energetic sources from the blood.  It is because 
of this that an angiogenesis process starts to supply 
the tumor according to its metabolic needs. This 
is where antiangiogenic therapy comes into play, 
thanks to genetic modification directed towards the 
endothelial cells near the tumor, acquiring the ability 
to synthesize substances that prevent the development 
of new controlled vessels and stopping excessive 
growth of the tumor. Some of the molecules used as 
antiangiogenics are angiostatin, batimastat or SU5416. 
However, this type of therapy is being studied as 
an adjunct to other more widespread therapies 
like chemotherapy or radiotherapy resulting in the 
combination of therapies such as cyclophosphamide, 
anti-cancer agents and TNP-470, an inhibitor of the 
migration and proliferation of vascular endothelium40. 
The use of PEI for obtaining non-viral vectors that 
transport these types of genetic materials has not only 
allowed the possibility of vehiculization but has also, 
in some cases, improved the transport over the use of 
other types of vectors 41.   
Tumor suppressor genes:  the process of 4. 
transformation from normal cell into a tumor is 
almost always mediated by two different genetic 
events: the alteration of proto-oncogenes leading to 
an abnormal cell division cycle or a mutation of the 
tumor suppressor genes that determines the protein 
synthesis incapable of controlling the cell cycle.  One 
of the possibilities of gene therapy lies in restoring 
the original genetic charge of the tumor cell with the 
subsequent reconversion to a healthy cell.  Although 
in theory this is possible, this type of approach has 
some issues that are still to be overcome.  It is possible 
that the most notable of these is the need for complete 
restitution or the genetics of each and every one of the 
cells. Otherwise, the continued growth of the tumor 
would not be prevented and it could return even if a 
single cell was not restored32.  
CONCLUSIONS
After reading this work, it is clear why interest has aroused 
in PEI research and, more specifically, in biomedical 
research.  Its characteristics and, mainly, its strong, positive 
surface electric charge, qualify it as a promising polymer 
for obtaining polymeric nanoparticles that act as non-
viral vectors in gene delivery.  This use, in turn, puts the 
spotlight on gene therapy and makes it participate in the 
treatment of many pathologies where it has made room for 
itself such as cancer, infections or cardiovascular diseases, 
among others.  Due to the strong presence of cancer in 
our society and the impact it has on it, this paper aims to 
illustrate how PEI similarly has a fundamental role in the 
fight against it.
However, not everything is said about the polymer 
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and, currently, numerous works are emerging about the 
improvement of gene delivery through the functionalization 
of PEI with different molecules yielding promising 
results42,43.
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